Cepheid Quarterly Earnings Top Analysts’ Estimates, Sending Shares Higher

Cepheid Inc. (CPHD), maker of a rapid test for the drug-resistant staph infection known as MRSA, surged 22 percent in early trading after the company yesterday reported fourth-quarter earnings that beat analysts’ estimates.

Cepheid rose $7.68 to $42.03 at 8:32 a.m. New York time. Earnings excluding one-time items of 14 cents a share beat by 10 cents the average of 12 analysts’ estimates compiled by Bloomberg.

Revenue jumped 36 percent to $80.1 million, on demand for its Xpert tests, the Sunnyvale, California-based company said in a statement yesterday. Methicillin-resistant Staphylococcus aureus, or MRSA, is primarily a hospital-acquired infection that sickens about 90,000 Americans annually, killing about 15,000, according to the Atlanta-based U.S. Centers for Disease Control and Prevention.

“We’ve increased our sales forecast following Cepheid’s strong fourth-quarter sales result,” wrote Dan Leonard, an analyst for Leerink Swann, in a note to investors today. He raised his 2012 and 2013 sales outlook after Cepheid’s hospital- acquired infections market beat his estimates in the fourth quarter, he wrote.

Cepheid had a net loss of $1.6 million, or 3 cents a share, reflecting a one-time charge associated with the end of a patent license, compared with net income of $1.3 million, or 2 cents, a year earlier, according to the statement.

To contact the reporter on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.